Early Phase Trial Finds Mirvetuximab Soravtansine Plus Bevacizumab

Early Phase Trial Finds Mirvetuximab Soravtansine Plus Bevacizumab The phase ib forward ii trial evaluated the antibody drug conjugate mirvetuximab soravtansine plus bevacizumab in patients with ovarian cancer who had disease progression after treatment with a platinum agent. The phase iii randomized gloriosa trial will evaluate mirv plus bevacizumab vs. bevacizumab alone as maintenance therapy in patients with frα high psoc who did not have disease progression following second line platinum based doublet chemotherapy plus bevacizumab.

Early Phase Trial Finds Mirvetuximab Soravtansine Plus Bevacizumab Nct02606305 is a multi arm, phase 1b 2 study evaluating the safety and tolerability of mirvetuximab soravtansine in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin, pembrolizumab, or bevacizumab plus carboplatin, in adults with frα expressing, advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. Purpose: evaluate the antitumor activity and safety profile of the combination of mirvetuximab soravtansine and bevacizumab in patients with platinum resistant ovarian cancer. Gloriosa is designed to randomize 418 patients, 1:1 receiving intravenous mirv at a dose of 6 mg kg adjusted ideal body weight plus bevacizumab 15mg kg every 3 weeks or receiving bevacizumab 15mg kg every 3 weeks until disease progression or unacceptable toxicity. Data from the confirmatory phase 3 mirasol trial (nct04209855) indicated that single agent mirvetuximab soravtansine had clinically meaningful activity and acceptable tolerability in.

Maintenance Mirvetuximab Soravtansine Plus Bevacizumab Under Gloriosa is designed to randomize 418 patients, 1:1 receiving intravenous mirv at a dose of 6 mg kg adjusted ideal body weight plus bevacizumab 15mg kg every 3 weeks or receiving bevacizumab 15mg kg every 3 weeks until disease progression or unacceptable toxicity. Data from the confirmatory phase 3 mirasol trial (nct04209855) indicated that single agent mirvetuximab soravtansine had clinically meaningful activity and acceptable tolerability in. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (frα) targeting antibody drug conjugate (adc), in combination with carboplatin in patients with platinum sensitive ovarian cancer. The phase 1b forward ii trial (nct02606305) evaluated the preliminary antitumor activity of the folate receptor alpha (frα)–targeting antibody–drug conjugate, mirvetuximab soravtansine (mirv), in combination with bevacizumab in patients with frα positive recurrent ovarian cancer. We conducted a phase 3, global, confirmatory, open label, randomized, controlled trial to compare the efficacy and safety of mirv with the investigator’s choice of chemotherapy in the treatment. Phase 3, randomized, single dose, open label study to investigate the safety and efficacy of pafolacianine sodium injection (otl38) for intraoperative imaging of folate receptor positive ovarian cancer.

Mirvetuximab Soravtansine Plus Bevacizumab Highly Active In Ovarian Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (frα) targeting antibody drug conjugate (adc), in combination with carboplatin in patients with platinum sensitive ovarian cancer. The phase 1b forward ii trial (nct02606305) evaluated the preliminary antitumor activity of the folate receptor alpha (frα)–targeting antibody–drug conjugate, mirvetuximab soravtansine (mirv), in combination with bevacizumab in patients with frα positive recurrent ovarian cancer. We conducted a phase 3, global, confirmatory, open label, randomized, controlled trial to compare the efficacy and safety of mirv with the investigator’s choice of chemotherapy in the treatment. Phase 3, randomized, single dose, open label study to investigate the safety and efficacy of pafolacianine sodium injection (otl38) for intraoperative imaging of folate receptor positive ovarian cancer.